metformin has been researched along with Adenoma, Prolactin-Secreting, Pituitary in 5 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Ten adult patients (26-61 years) with prolactinomas (7 M), persistent hyperprolactinemia (38-386 ng/mL) under cabergoline treatment (2-7 mg/week) for at least 6 months (6-108 months), features of metabolic syndrome, and not taking metformin were included." | 4.12 | Prolactin Response to Metformin in Cabergoline-Resistant Prolactinomas: A Pilot Study. ( Abucham, J; Correa-Silva, SR; Portari, LHC, 2022) |
| "Prolactinomas are the most common functional pituitary adenomas and dopamine agonists are the primary therapy." | 1.48 | Combination Treatment with Bromocriptine and Metformin in Patients with Bromocriptine-Resistant Prolactinomas: Pilot Study. ( Bao, X; Deng, K; Feng, M; Gao, J; Liu, X; Liu, Y; Wang, R; Yao, Y, 2018) |
| "Metformin (MET) is a diabetes drug that activates AMP-activated protein kinase (AMPK), and is suggested to have anticancer efficacy." | 1.48 | Metformin inhibits growth and prolactin secretion of pituitary prolactinoma cells and xenografts. ( Bao, X; Deng, K; Feng, M; Gao, J; Han, G; Lian, W; Liu, X; Liu, Y; Lv, X; Wang, R; Xing, B; Yao, Y, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Portari, LHC | 1 |
| Correa-Silva, SR | 1 |
| Abucham, J | 1 |
| Jin, K | 1 |
| Ruan, L | 1 |
| Pu, J | 1 |
| Zhong, A | 1 |
| Wang, F | 1 |
| Tan, S | 1 |
| Huang, H | 1 |
| Mou, J | 1 |
| Yang, G | 1 |
| Liu, X | 2 |
| Liu, Y | 2 |
| Gao, J | 2 |
| Feng, M | 2 |
| Bao, X | 2 |
| Deng, K | 2 |
| Yao, Y | 2 |
| Wang, R | 2 |
| Han, G | 1 |
| Lian, W | 1 |
| Xing, B | 1 |
| Lv, X | 1 |
| Krysiak, R | 1 |
| Szkróbka, W | 1 |
| Okopień, B | 1 |
5 other studies available for metformin and Adenoma, Prolactin-Secreting, Pituitary
| Article | Year |
|---|---|
Prolactin Response to Metformin in Cabergoline-Resistant Prolactinomas: A Pilot Study.
Topics: Adult; Cabergoline; Dopamine Agonists; Drug Resistance; Drug Therapy, Combination; Female; Humans; H | 2022 |
[Effect of metformin on proliferation and apoptosis of rat prolactinoma MMQ cells and related mechanisms].
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Metformin; Prolactinoma; Rats | 2017 |
Combination Treatment with Bromocriptine and Metformin in Patients with Bromocriptine-Resistant Prolactinomas: Pilot Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bromocriptine; Female; Humans; Male; Metformi | 2018 |
Metformin inhibits growth and prolactin secretion of pituitary prolactinoma cells and xenografts.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Apoptosis; Bromocriptine; Cell Proliferation; Estroge | 2018 |
A Neutral Effect of Metformin Treatment on Macroprolactin Content in Women with Macroprolactinemia.
Topics: Adult; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hyperprolactinemia; Metformi | 2017 |